Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.
The company was incorporated in 2018 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 264 |
| CEO | Christopher Peetz |
Contact Details
Address: 950 Tower Lane, Suite 1050 Foster City, California 94404 United States | |
| Phone | 650-667-4085 |
| Website | mirumpharma.com |
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| Employer ID | 83-1281555 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer and Director |
| Peter Radovich M.B.A., Ph.D. | Chief Operating Officer and President |
| Dr. Pamela Vig Ph.D. | Chief Scientific Officer and Head of Research |
| Lara Longpre MBA, MSC | Chief Development Officer |
| Eric H. Bjerkholt M.B.A. | Chief Financial Officer |
| Andrew McKibben | Vice President of Investor Relations and Finance |
| Paul K. Ross | Chief Compliance Officer |
| Erin Campany | Senior Vice President of Human Resources |
| Dr. Ian Clements Ph.D. | Consultant |
| Vinita P. Kumar | Senior vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 15, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 16, 2024 | 8-K | Current Report |
| Jan 8, 2024 | 8-K | Current Report |
| Dec 29, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |